Glaukos has re-accelerated revenue to $211.0M in 2026Q3, up 58.0% year over year, while gross margin expanded from 72.9% in 2024Q4 to 85.2%, suggesting improving unit economics and emerging operating leverage.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth re-accelerated to 58.0% in 2026Q3 with gross margin expanding to 85.2%, yet the operating margin of just 0.4% and a 2025Q4 net loss of $133.7M suggest profitability remains fragile.
Glaukos focuses on developing novel therapies to advance the standard of care in the global ophthalmic market, enriching patient treatment alternatives.
The investment case for Glaukos is supported by solid fundamentals, valuation multiples, and analyst positioning, indicating potential growth.
Positive smart-money flows into Glaukos suggest institutional confidence in the company's long-term prospects.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 28, 2026 | $0.47+587.8% vs -$0.10 | $211M+25.6% vs $168M |
Q3 2026 Jul 29, 2026 | -$0.14+33.5% vs -$0.21 | $186M+23.0% vs $151M |
Q2 2026 Apr 29, 2026 | -$0.18+40.0% vs -$0.30 | $151M+9.9% vs $137M |
Q1 2026 Feb 17, 2026 | -$0.28-27.3% vs -$0.22 | $143M+4.9% vs $136M |
State of Alaska Department of Revenue lowered its stake in Glaukos Corporation (NYSE: GKOS) by 48.6% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,950 shares of the medical instruments supplier's stock after selling 9,393 shares during the period. State of Alaska
GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher guidance and promising clinical developments.
Glaukos is transitioning from a single-product reimbursement story to a diversified ophthalmic pharmaceutical platform with two J-coded drugs and strong operating leverage. Q2 net sales grew 50% YoY to $185.6M, driven by iDose TR and the Epioxa launch, with non-GAAP gross margin reaching 85% and breakeven P&L. Management raised 2026 net sales guidance to $680–700M, with iDose TR sales expected at $275–280M and corneal health growth of 20%+.
GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.
Benchmark GKOS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Glaukos Corporation (GKOS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $224.41 | $13.24B | -80.88 | 32.33% | -24.6% | -24.91% | — | |
| $58.54 | $2.98B | 195.98 | 14.88% | 2.52% | 2.93% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $16.91 | $1.16B | -23.92 | 7.93% | -4.58% | -35.61% | — | |
| $63.98 | $1.84B | 18.38 | 13.6% | 11.43% | 12.49% | — | |
| $102.14 | $58.81B | 57.77 | 11.55% | 15.3% | 9.65% | — |
Glaukos Corporation (GKOS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Glaukos Corporation (GKOS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 28, 2026·SEC
Jul 29, 2026·SEC
Jun 3, 2026·SEC
Get notified when GKOS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Glaukos Corporation (GKOS) stock FAQ — growth, dividends, profitability & financials explained
Glaukos Corporation (GKOS) reported $690.3M in revenue over the trailing twelve months. Revenue was $507.4M in fiscal year 2025. That is 20791% more than the $2.4M of fiscal year 2012.
Glaukos Corporation (GKOS) grew revenue by 46.9% over the trailing twelve months, compared with the twelve months before.
No. Glaukos Corporation (GKOS) reported a net loss of $169.8M over the trailing twelve months.
Glaukos Corporation (GKOS) had a return on equity (ROE) of -24.9% over the trailing twelve months. A negative ROE means the company lost money over the period.
Glaukos Corporation (GKOS) generated $36.0M in free cash flow over the trailing twelve months.
